OVCAS1
MCID: OVR114
MIFTS: 38

Ovarian Cancer 1 (OVCAS1)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer 1

MalaCards integrated aliases for Ovarian Cancer 1:

Name: Ovarian Cancer 1 56 29
Ovarian Cancer, Susceptibility to, 1 56 13
Ovarian Cancer, Susceptibility to 56
Malignant Neoplasm of Ovary 71
Epithelial Ovarian Cancer 71
Ovarian Carcinoma 71
Ovarian Cancer 56
Ovcas1 56

Classifications:



External Ids:

OMIM 56 607893
UMLS 71 C0029925 C0677886 C1140680

Summaries for Ovarian Cancer 1

MalaCards based summary : Ovarian Cancer 1, also known as ovarian cancer, susceptibility to, 1, is related to ovarian cancer and hereditary breast ovarian cancer syndrome, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer 1 is OVCAS1 (Ovarian Cancer, Epithelial, Susceptibility To). The drugs Diclofenac and Aprepitant have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and lung.

More information from OMIM: 607893

Related Diseases for Ovarian Cancer 1

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Familial Ovarian Cancer

Diseases related to Ovarian Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 925, show less)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 27.4 PHF13 OVCAS1 FILIP1L DPH1
2 hereditary breast ovarian cancer syndrome 12.8
3 breast-ovarian cancer, familial 2 12.7
4 breast-ovarian cancer, familial 3 12.6
5 breast-ovarian cancer, familial 4 12.6
6 familial ovarian cancer 12.3
7 hereditary site-specific ovarian cancer syndrome 12.2
8 ovarian epithelial cancer 12.1
9 fallopian tube carcinoma 11.7
10 pancreatic cancer 11.6
11 paraneoplastic cerebellar degeneration 11.6
12 ovarian small cell carcinoma 11.6
13 ovarian germ cell cancer 11.6
14 breast cancer 11.5
15 lynch syndrome 11.5
16 ovarian disease 11.5
17 ovarian melanoma 11.4
18 malignant ovarian cyst 11.4
19 ovarian lymphoma 11.4
20 malignant teratoma 11.4
21 breast-ovarian cancer, familial 1 11.3
22 enchondromatosis, multiple, ollier type 11.1
23 sex cord-gonadal stromal tumor 11.1
24 atypical teratoid rhabdoid tumor 11.1
25 ovarian malignant mesothelioma 11.1
26 ovary sarcoma 11.1
27 ovary epithelial cancer 11.1
28 ovary neuroendocrine neoplasm 11.1
29 ovarian clear cell malignant adenofibroma 11.1
30 granulosa cell tumor of the ovary 11.1
31 gynandroblastoma 11.1
32 neutropenia 11.0
33 endometriosis 10.9
34 serous cystadenocarcinoma 10.9
35 endometrial cancer 10.8
36 ovary adenocarcinoma 10.8
37 adenocarcinoma 10.8
38 cystadenocarcinoma 10.8
39 alopecia 10.7
40 ovarian cyst 10.7
41 neuropathy 10.7
42 peripheral nervous system disease 10.7
43 thrombocytopenia 10.7
44 malignant epithelial tumor of ovary 10.7
45 infertility 10.6
46 severe combined immunodeficiency 10.6
47 mucositis 10.6
48 primary peritoneal carcinoma 10.6
49 b-cell lymphoma 10.6
50 peritonitis 10.6
51 ovarian serous carcinoma 10.6
52 cystadenoma 10.6
53 47,xyy 10.5
54 ovarian serous cystadenocarcinoma 10.5
55 colorectal cancer 10.5
56 body mass index quantitative trait locus 1 10.5
57 mucinous cystadenocarcinoma 10.5
58 mucinous adenocarcinoma 10.5
59 appendix adenocarcinoma 10.5
60 clear cell adenocarcinoma 10.5
61 constipation 10.5
62 thrombocytosis 10.5
63 retinoblastoma 10.5
64 familial retinoblastoma 10.5
65 intestinal obstruction 10.5
66 stomatitis 10.5
67 cervical cancer 10.5
68 allergic hypersensitivity disease 10.5
69 ovarian cystadenocarcinoma 10.5
70 hypoxia 10.5
71 pulmonary embolism 10.4
72 exanthem 10.4
73 sensory peripheral neuropathy 10.4
74 cytokine deficiency 10.4
75 pelvic inflammatory disease 10.4
76 diarrhea 10.4
77 adenoma 10.4
78 insulin-like growth factor i 10.4
79 pik3ca-related overgrowth syndrome 10.4
80 fanconi anemia, complementation group a 10.4
81 herpes simplex 10.4
82 benign mesothelioma 10.4
83 teratoma 10.4
84 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
85 endometriosis of ovary 10.4
86 granulocytopenia 10.4
87 mast cell activation syndrome 10.4
88 ataxia and polyneuropathy, adult-onset 10.4
89 dermatomyositis 10.4
90 bilateral breast cancer 10.4
91 ileus 10.4
92 48,xyyy 10.3
93 telangiectasis 10.3
94 papillary adenocarcinoma 10.3
95 papillary carcinoma 10.3
96 ataxia-telangiectasia 10.3
97 leukemia 10.3
98 leukemia, acute myeloid 10.3
99 pertussis 10.3
100 cerebellar degeneration 10.3
101 thrombophilia due to thrombin defect 10.3
102 triiodothyronine receptor auxiliary protein 10.3
103 carcinosarcoma 10.3
104 body mass index quantitative trait locus 11 10.3
105 chlamydia 10.3
106 dysgerminoma 10.3
107 bladder cancer 10.3
108 lung cancer susceptibility 3 10.3
109 female breast cancer 10.3
110 polycystic ovary syndrome 10.3
111 papillary serous adenocarcinoma 10.3
112 testicular cancer 10.3
113 germ cells tumors 10.3
114 rapidly involuting congenital hemangioma 10.3
115 prostate cancer 10.2
116 suppressor of tumorigenicity 3 10.2
117 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.2
118 wilms tumor 5 10.2
119 renal cell carcinoma, nonpapillary 10.2
120 lung cancer 10.2
121 fanconi anemia, complementation group d2 10.2
122 body mass index quantitative trait locus 9 10.2
123 body mass index quantitative trait locus 8 10.2
124 body mass index quantitative trait locus 4 10.2
125 body mass index quantitative trait locus 10 10.2
126 body mass index quantitative trait locus 7 10.2
127 body mass index quantitative trait locus 12 10.2
128 body mass index quantitative trait locus 14 10.2
129 myelodysplastic syndrome 10.2
130 body mass index quantitative trait locus 18 10.2
131 body mass index quantitative trait locus 19 10.2
132 body mass index quantitative trait locus 20 10.2
133 sexual disorder 10.2
134 ectopic pregnancy 10.2
135 thrombosis 10.2
136 cystic teratoma 10.2
137 ovarian cystadenoma 10.2
138 teratocarcinoma 10.2
139 sporadic breast cancer 10.2
140 in situ carcinoma 10.2
141 mesothelioma, malignant 10.2
142 ectodermal dysplasia-syndactyly syndrome 2 10.2
143 leiomyoma 10.2
144 glioblastoma multiforme 10.2
145 papilloma 10.2
146 actinomycosis 10.2
147 anxiety 10.2
148 familial adenomatous polyposis 10.2
149 pancytopenia 10.2
150 acute leukemia 10.2
151 myoma 10.2
152 lymphopenia 10.2
153 myeloid leukemia 10.2
154 clear cell adenocarcinoma of the ovary 10.2
155 hepatocellular carcinoma 10.2
156 li-fraumeni syndrome 10.2
157 proteasome-associated autoinflammatory syndrome 1 10.2
158 retinitis pigmentosa 11 10.2
159 li-fraumeni syndrome 2 10.2
160 mumps 10.2
161 kidney cancer 10.2
162 tic disorder 10.2
163 osteogenic sarcoma 10.1
164 mycobacterium tuberculosis 1 10.1
165 lymphoma 10.1
166 pain agnosia 10.1
167 hydronephrosis 10.1
168 pneumothorax 10.1
169 endometrial adenocarcinoma 10.1
170 vaccinia 10.1
171 measles 10.1
172 acute sensory ataxic neuropathy 10.1
173 xeroderma pigmentosum, variant type 10.1
174 epileptic encephalopathy, childhood-onset 10.1
175 deficiency anemia 10.1
176 small cell carcinoma 10.1
177 disseminated intravascular coagulation 10.1
178 squamous cell papilloma 10.1
179 pleural disease 10.1
180 rectum cancer 10.1
181 intestinal perforation 10.1
182 papillary cystadenocarcinoma 10.1
183 skin carcinoma 10.1
184 ovarian clear cell adenocarcinoma 10.1
185 mature teratoma 10.1
186 hyperthyroidism 10.1
187 malignancy diagnosed during pregnancy 10.1
188 argyria 10.1
189 rare tumor 10.1
190 polyploidy 10.1
191 ascites, chylous 10.1
192 adenomyosis 10.1
193 pachyonychia congenita 3 10.1
194 helix syndrome 10.1
195 diaphragm disease 10.1
196 hemiplegia 10.1
197 diphtheria 10.1
198 toxic shock syndrome 10.1
199 peritoneal mesothelioma 10.1
200 acute kidney failure 10.1
201 ovarian mucinous cystadenocarcinoma 10.1
202 hypokalemia 10.1
203 neuroblastoma 10.1
204 tuberculous peritonitis 10.1
205 lymph node disease 10.1
206 paraneoplastic syndromes 10.1
207 small cell cancer of the lung 10.1
208 fanconi anemia, complementation group c 10.1
209 thymoma, familial 10.1
210 gastric cancer 10.1
211 pulmonary hypertension 10.1
212 aphasia 10.1
213 hereditary lymphedema i 10.1
214 premature menopause 10.1
215 sarcoma 10.1
216 squamous cell carcinoma 10.1
217 endodermal sinus tumor 10.1
218 ovarian brenner tumor 10.1
219 germ cell cancer 10.1
220 thymoma 10.1
221 anovulation 10.1
222 myopathy 10.1
223 liver cirrhosis 10.1
224 congestive heart failure 10.1
225 diabetes mellitus 10.1
226 soft tissue sarcoma 10.1
227 encephalopathy 10.1
228 virus-associated trichodysplasia spinulosa 10.1
229 esophageal cancer 10.0
230 polycystic liver disease 1 with or without kidney cysts 10.0
231 multiple pterygium syndrome, lethal type 10.0
232 myeloma, multiple 10.0
233 wiskott-aldrich syndrome 10.0
234 gastrointestinal stromal tumor 10.0
235 ductal carcinoma in situ 10.0
236 endometrial hyperplasia 10.0
237 endocarditis 10.0
238 rickets 10.0
239 estrogen excess 10.0
240 hypothyroidism 10.0
241 cholera 10.0
242 cystitis 10.0
243 melanoma 10.0
244 leiomyosarcoma 10.0
245 pseudomyxoma peritonei 10.0
246 hyperglycemia 10.0
247 spindle cell sarcoma 10.0
248 kidney disease 10.0
249 endometrioid ovary carcinoma 10.0
250 inflammatory breast carcinoma 10.0
251 neurofibromatosis 10.0
252 uterine corpus cancer 10.0
253 fasciitis 10.0
254 back pain 10.0
255 thrombotic microangiopathy 10.0
256 thyroid carcinoma 10.0
257 autoimmune disease 10.0
258 teratoma, ovarian 10.0
259 wilms tumor 1 10.0
260 lymphoma, hodgkin, classic 10.0
261 lymphoma, non-hodgkin, familial 10.0
262 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
263 estrogen resistance 10.0
264 covid-19 10.0
265 benign teratoma 10.0
266 nephrotic syndrome 10.0
267 hemosiderosis 10.0
268 hemolytic-uremic syndrome 10.0
269 acute cystitis 10.0
270 brain cancer 10.0
271 keratosis 10.0
272 hyperinsulinism 10.0
273 transitional cell carcinoma 10.0
274 myofibroma 10.0
275 ovarian germ cell teratoma 10.0
276 hemolytic anemia 10.0
277 meningitis 10.0
278 krukenberg carcinoma 10.0
279 malignant peritoneal mesothelioma 10.0
280 cerebrofacial arteriovenous metameric syndrome 10.0
281 rare hereditary hemochromatosis 10.0
282 acanthosis nigricans 9.9
283 neurofibromatosis, type ii 9.9
284 lynch syndrome i 9.9
285 hypercholesterolemia, familial, 1 9.9
286 sarcoidosis 1 9.9
287 thrombocytopenia 3 9.9
288 prostatic hyperplasia, benign 9.9
289 branchiootic syndrome 1 9.9
290 fanconi anemia, complementation group n 9.9
291 graft-versus-host disease 9.9
292 leukemia, acute lymphoblastic 3 9.9
293 cholangiocarcinoma 9.9
294 colorectal adenoma 9.9
295 oral squamous cell carcinoma 9.9
296 fibroma 9.9
297 pre-eclampsia 9.9
298 microcephaly 9.9
299 prostatic hypertrophy 9.9
300 respiratory failure 9.9
301 echinococcosis 9.9
302 duodenal ulcer 9.9
303 peritoneum cancer 9.9
304 neuroendocrine carcinoma 9.9
305 post-traumatic stress disorder 9.9
306 colon adenocarcinoma 9.9
307 basal cell carcinoma 9.9
308 splenic disease 9.9
309 prostatic adenoma 9.9
310 pulmonary tuberculosis 9.9
311 sertoli-leydig cell tumor 9.9
312 gallbladder cancer 9.9
313 fibrosarcoma 9.9
314 liposarcoma 9.9
315 breast disease 9.9
316 choriocarcinoma 9.9
317 cervical adenocarcinoma 9.9
318 pancreatic adenocarcinoma 9.9
319 systemic scleroderma 9.9
320 lymphocele 9.9
321 adenosquamous carcinoma 9.9
322 intrahepatic cholangiocarcinoma 9.9
323 ureteral obstruction 9.9
324 testicular yolk sac tumor 9.9
325 clear cell adenofibroma 9.9
326 cystadenofibroma 9.9
327 acute stress disorder 9.9
328 chromosomal triplication 9.9
329 glioma 9.9
330 polymyositis 9.9
331 pituitary tumors 9.9
332 syncope 9.9
333 primary peritoneal tumor 9.9
334 glial tumor 9.9
335 inflammatory myopathy with abundant macrophages 9.9
336 alcohol dependence 9.9
337 burkitt lymphoma 9.9
338 gastric cancer, hereditary diffuse 9.9
339 huntington disease 9.9
340 kaposi sarcoma 9.9
341 leiomyoma, uterine 9.9
342 medulloblastoma 9.9
343 osteoporosis 9.9
344 polykaryocytosis inducer 9.9
345 scleroderma, familial progressive 9.9
346 enterocolitis 9.9
347 hemochromatosis, type 1 9.9
348 microcephaly 1, primary, autosomal recessive 9.9
349 xeroderma pigmentosum, complementation group c 9.9
350 yemenite deaf-blind hypopigmentation syndrome 9.9
351 oculomedin 9.9
352 paragangliomas 3 9.9
353 nasopharyngeal carcinoma 9.9
354 coronary heart disease 1 9.9
355 myocardial infarction 9.9
356 fanconi anemia, complementation group i 9.9
357 fanconi anemia, complementation group j 9.9
358 acute promyelocytic leukemia 9.9
359 leptin deficiency or dysfunction 9.9
360 tatton-brown-rahman syndrome 9.9
361 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.9
362 thrombocytopenia 6 9.9
363 cutaneous t cell lymphoma 9.9
364 marantic endocarditis 9.9
365 estrogen-receptor positive breast cancer 9.9
366 colitis 9.9
367 clostridium difficile colitis 9.9
368 cardiac arrest 9.9
369 lactose intolerance 9.9
370 short bowel syndrome 9.9
371 mastitis 9.9
372 tetanus 9.9
373 endosalpingiosis 9.9
374 hyperandrogenism 9.9
375 patent foramen ovale 9.9
376 polyneuropathy 9.9
377 amenorrhea 9.9
378 urticaria 9.9
379 mental depression 9.9
380 adenosarcoma 9.9
381 struma ovarii 9.9
382 purpura 9.9
383 cellulitis 9.9
384 ovarian mucinous adenocarcinoma 9.9
385 malignant ovarian brenner tumor 9.9
386 intracranial embolism 9.9
387 salpingitis 9.9
388 thyroid hyalinizing trabecular adenoma 9.9
389 small-cell carcinoma of the ovary of hypercalcemic type 9.9
390 appendicitis 9.9
391 lung disease 9.9
392 vasculitis 9.9
393 gas gangrene 9.9
394 encephalitis 9.9
395 pathologic nystagmus 9.9
396 hypereosinophilic syndrome 9.9
397 ovarian remnant syndrome 9.9
398 tetraploidy 9.9
399 depression 9.9
400 dysphagia 9.9
401 pseudo-meigs syndrome 9.9
402 mucinous adenocarcinoma of ovary 9.9
403 overgrowth syndrome 9.9
404 atrial standstill 1 9.8
405 carcinoid tumors, intestinal 9.8
406 multiple endocrine neoplasia, type i 9.8
407 glioma susceptibility 1 9.8
408 hair whorl 9.8
409 palmoplantar keratoderma, epidermolytic 9.8
410 leukemia, chronic lymphocytic 9.8
411 lipomatosis, multiple 9.8
412 systemic lupus erythematosus 9.8
413 optic atrophy 1 9.8
414 thrombocytopenic purpura, autoimmune 9.8
415 down syndrome 9.8
416 anemia, autoimmune hemolytic 9.8
417 bloom syndrome 9.8
418 celiac disease 1 9.8
419 chondrosarcoma 9.8
420 coloboma, ocular, autosomal recessive 9.8
421 factor vii deficiency 9.8
422 multiple acyl-coa dehydrogenase deficiency 9.8
423 nijmegen breakage syndrome 9.8
424 myelofibrosis 9.8
425 3-methylglutaconic aciduria, type iii 9.8
426 xeroderma pigmentosum, complementation group d 9.8
427 premature ovarian failure 1 9.8
428 gonadoblastoma 9.8
429 aging 9.8
430 stroke, ischemic 9.8
431 creatinine clearance quantitative trait locus 9.8
432 epidermolysis bullosa simplex superficialis 9.8
433 major depressive disorder 9.8
434 human immunodeficiency virus type 1 9.8
435 colorectal cancer 2 9.8
436 bone mineral density quantitative trait locus 8 9.8
437 thrombocytopenia 4 9.8
438 colorectal cancer 3 9.8
439 leukemia, acute lymphoblastic 9.8
440 bone mineral density quantitative trait locus 15 9.8
441 fanconi anemia, complementation group l 9.8
442 pancreatic cancer 4 9.8
443 diarrhea 6 9.8
444 melanoma, cutaneous malignant 10 9.8
445 mulchandani-bhoj-conlin syndrome 9.8
446 fanconi anemia, complementation group s 9.8
447 diarrhea 9 9.8
448 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.8
449 chronic diarrhea due to guanylate cyclase 2c overactivity 9.8
450 angiosarcoma 9.8
451 aspiration pneumonia 9.8
452 hypophosphatemia 9.8
453 tooth agenesis 9.8
454 extrapulmonary tuberculosis 9.8
455 autosomal recessive disease 9.8
456 diffuse large b-cell lymphoma 9.8
457 mantle cell lymphoma 9.8
458 hemorrhagic cystitis 9.8
459 large cell neuroendocrine carcinoma 9.8
460 follicular lymphoma 9.8
461 endocervical adenocarcinoma 9.8
462 ovarian benign neoplasm 9.8
463 inguinal hernia 9.8
464 bone disease 9.8
465 bone resorption disease 9.8
466 ovarian sex-cord stromal tumor 9.8
467 osteonecrosis 9.8
468 pleomorphic lipoma 9.8
469 parotitis 9.8
470 asbestosis 9.8
471 bacterial infectious disease 9.8
472 nasopharyngitis 9.8
473 charcot-marie-tooth disease 9.8
474 glucose intolerance 9.8
475 hypertrophy of breast 9.8
476 portal hypertension 9.8
477 methemoglobinemia 9.8
478 cardiac tamponade 9.8
479 coronary thrombosis 9.8
480 vaginal cancer 9.8
481 pica disease 9.8
482 eclampsia 9.8
483 obstructive jaundice 9.8
484 neuritis 9.8
485 calcinosis 9.8
486 hypogonadism 9.8
487 hepatitis b 9.8
488 pharyngitis 9.8
489 thrombophilia 9.8
490 motor peripheral neuropathy 9.8
491 leydig cell tumor 9.8
492 bilirubin metabolic disorder 9.8
493 cervix carcinoma 9.8
494 newcastle disease 9.8
495 cockayne syndrome 9.8
496 female reproductive endometrioid cancer 9.8
497 multiple endocrine neoplasia 9.8
498 proctitis 9.8
499 lipid metabolism disorder 9.8
500 oligodendroglioma 9.8
501 neurilemmoma 9.8
502 rhabdomyosarcoma 9.8
503 ischemia 9.8
504 embryonal carcinoma 9.8
505 mood disorder 9.8
506 mesenchymal cell neoplasm 9.8
507 palmoplantar keratosis 9.8
508 signet ring cell adenocarcinoma 9.8
509 lactic acidosis 9.8
510 fallopian tube adenocarcinoma 9.8
511 plasmacytoma 9.8
512 vaginal discharge 9.8
513 pulmonary fibrosis 9.8
514 liver disease 9.8
515 syphilis 9.8
516 amelanotic melanoma 9.8
517 clear cell renal cell carcinoma 9.8
518 uremia 9.8
519 tubular adenocarcinoma 9.8
520 pneumonia 9.8
521 fallopian tube serous adenocarcinoma 9.8
522 nephrolithiasis 9.8
523 juvenile type testicular granulosa cell tumor 9.8
524 mucinous cystadenofibroma 9.8
525 cerebrovascular disease 9.8
526 malignant pleural mesothelioma 9.8
527 muscular atrophy 9.8
528 chronic kidney disease 9.8
529 subacute delirium 9.8
530 breast carcinoma in situ 9.8
531 lupus erythematosus 9.8
532 lymphangitis 9.8
533 noma 9.8
534 hypoglycemia 9.8
535 pik3ca-related segmental overgrowth 9.8
536 acute graft versus host disease 9.8
537 limbic encephalitis 9.8
538 opsoclonus-myoclonus syndrome 9.8
539 oral cancer 9.8
540 raynaud phenomenon 9.8
541 cytomegalovirus infection 9.8
542 headache 9.8
543 myoclonus 9.8
544 asbestos intoxication 9.8
545 ovarian fibrothecoma 9.8
546 chronic enteropathy associated with slco2a1 gene 9.8
547 primary peritoneal serous/papillary carcinoma 9.8
548 benign idiopathic neonatal seizures 9.8
549 cancer-associated retinopathy 9.8
550 ovarian clear cell carcinoma 9.8
551 pfeiffer syndrome 9.6
552 tooth agenesis, selective, 1 9.6
553 atherosclerosis susceptibility 9.6
554 gastroesophageal reflux 9.6
555 epidermolytic hyperkeratosis 9.6
556 progressive familial heart block, type ia 9.6
557 cardiac arrhythmia 9.6
558 cardiofaciocutaneous syndrome 1 9.6
559 clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly 9.6
560 craniosynostosis 1 9.6
561 optic atrophy with or without deafness, ophthalmoplegia, myopathy, ataxia, and neuropathy 9.6
562 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 9.6
563 diabetes mellitus, noninsulin-dependent 9.6
564 preauricular fistulae, congenital 9.6
565 endometriosis 1 9.6
566 exostoses, multiple, type i 9.6
567 fibrosis of extraocular muscles, congenital, 1 9.6
568 hpa i recognition polymorphism, beta-globin-related 9.6
569 intussusception 9.6
570 tylosis with esophageal cancer 9.6
571 melanoma, uveal 9.6
572 migraine with or without aura 1 9.6
573 nondisjunction 9.6
574 muir-torre syndrome 9.6
575 myositis 9.6
576 neutrophilia, hereditary 9.6
577 noonan syndrome 1 9.6
578 ocular cicatricial pemphigoid 9.6
579 nephrolithiasis, calcium oxalate 9.6
580 peutz-jeghers syndrome 9.6
581 pelvic organ prolapse 9.6
582 pulmonary fibrosis, idiopathic 9.6
583 dowling-degos disease 1 9.6
584 schizophrenia 9.6
585 scoliosis, isolated 1 9.6
586 spherocytosis, type 1 9.6
587 neural tube defects 9.6
588 split-hand/foot malformation 1 9.6
589 thrombocytopenia 2 9.6
590 digeorge syndrome 9.6
591 tobacco addiction 9.6
592 varicose veins 9.6
593 vitiligo-associated multiple autoimmune disease susceptibility 6 9.6
594 volvulus of midgut 9.6
595 von hippel-lindau syndrome 9.6
596 wolff-parkinson-white syndrome 9.6
597 zinc finger protein 1 9.6
598 anemia, hypochromic microcytic, with iron overload 1 9.6
599 cystic fibrosis 9.6
600 fructose utilization 9.6
601 galactosemia i 9.6
602 immune deficiency disease 9.6
603 lambert syndrome 9.6
604 laryngoonychocutaneous syndrome 9.6
605 spondylometaphyseal dysplasia, sedaghatian type 9.6
606 myasthenia gravis 9.6
607 carnitine palmitoyltransferase i deficiency 9.6
608 myopathy, myosin storage, autosomal recessive 9.6
609 ocular motor apraxia 9.6
610 reticulum cell sarcoma 9.6
611 enhanced s-cone syndrome 9.6
612 smith-lemli-opitz syndrome 9.6
613 testicular germ cell tumor 9.6
614 xeroderma pigmentosum, complementation group f 9.6
615 fanconi anemia, complementation group b 9.6
616 sarcoma, synovial 9.6
617 mend syndrome 9.6
618 androgen insensitivity, partial 9.6
619 reticuloendotheliosis, x-linked 9.6
620 retinoschisis 1, x-linked, juvenile 9.6
621 46,xy sex reversal 1 9.6
622 palmoplantar keratoderma, bothnian type 9.6
623 gallbladder disease 1 9.6
624 asthma 9.6
625 fanconi anemia, complementation group e 9.6
626 pleuropulmonary blastoma 9.6
627 paragangliomas 2 9.6
628 tooth agenesis, selective, 2 9.6
629 macular degeneration, age-related, 1 9.6
630 homocysteinemia 9.6
631 fanconi anemia, complementation group f 9.6
632 papillary thyroid microcarcinoma 9.6
633 meningioma, radiation-induced 9.6
634 vitiligo-associated multiple autoimmune disease susceptibility 1 9.6
635 lymphangioleiomyomatosis 9.6
636 bone mineral density quantitative trait locus 3 9.6
637 meningioma, familial 9.6
638 kala-azar 1 9.6
639 leukemia, chronic myeloid 9.6
640 aplastic anemia 9.6
641 hepatitis c virus 9.6
642 xeroderma pigmentosum, complementation group b 9.6
643 alzheimer disease 14 9.6
644 short-rib thoracic dysplasia 2 with or without polydactyly 9.6
645 smoking as a quantitative trait locus 3 9.6
646 ewing sarcoma 9.6
647 colorectal cancer 11 9.6
648 myxoid liposarcoma 9.6
649 fanconi anemia, complementation group p 9.6
650 cyanosis, transient neonatal 9.6
651 nestor-guillermo progeria syndrome 9.6
652 colorectal cancer, hereditary nonpolyposis, type 5 9.6
653 accelerated tumor formation 9.6
654 membranous nephropathy 9.6
655 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.6
656 fanconi anemia, complementation group q 9.6
657 craniosynostosis 3 9.6
658 myopathy, isolated mitochondrial, autosomal dominant 9.6
659 thrombocytopenia 5 9.6
660 joint laxity, short stature, and myopia 9.6
661 angina pectoris 9.6
662 cutaneous lupus erythematosus 9.6
663 lambert-eaton myasthenic syndrome 9.6
664 arrhythmogenic right ventricular cardiomyopathy 9.6
665 hypochromic microcytic anemia 9.6
666 peripheral t-cell lymphoma 9.6
667 metabolic acidosis 9.6
668 zollinger-ellison syndrome 9.6
669 secondary progressive multiple sclerosis 9.6
670 limb ischemia 9.6
671 gastrointestinal carcinoma 9.6
672 infective endocarditis 9.6
673 estrogen-receptor negative breast cancer 9.6
674 generalized epilepsy with febrile seizures plus 9.6
675 crohn's colitis 9.6
676 scoliosis 9.6
677 idiopathic scoliosis 9.6
678 gallbladder disease 9.6
679 umbilical hernia 9.6
680 drug allergy 9.6
681 autosomal dominant non-syndromic intellectual disability 1 9.6
682 primary microcephaly 9.6
683 childhood acute lymphocytic leukemia 9.6
684 tongue carcinoma 9.6
685 split hand-foot malformation 9.6
686 sensorineural hearing loss 9.6
687 ampulla of vater cancer 9.6
688 cholelithiasis 9.6
689 pleurisy 9.6
690 viral meningitis 9.6
691 chronic leukemia 9.6
692 prolymphocytic leukemia 9.6
693 osteomalacia 9.6
694 thrombotic thrombocytopenic purpura 9.6
695 gastric ulcer 9.6
696 abducens nerve disease 9.6
697 tooth disease 9.6
698 amnestic disorder 9.6
699 primary hyperparathyroidism 9.6
700 appendix cancer 9.6
701 arteriovenous malformation 9.6
702 pneumocystosis 9.6
703 spinal meningioma 9.6
704 pulmonary edema 9.6
705 pyelonephritis 9.6
706 hemopericardium 9.6
707 portal vein thrombosis 9.6
708 choledocholithiasis 9.6
709 pericardial effusion 9.6
710 protein-energy malnutrition 9.6
711 multicentric reticulohistiocytosis 9.6
712 myopia 9.6
713 clubfoot 9.6
714 gastroparesis 9.6
715 esophagitis 9.6
716 hypertrophic cardiomyopathy 9.6
717 neurogenic bladder 9.6
718 lymphocytic choriomeningitis 9.6
719 oligohydramnios 9.6
720 graves' disease 9.6
721 vulva cancer 9.6
722 bell's palsy 9.6
723 hepatic coma 9.6
724 nephrocalcinosis 9.6
725 dilated cardiomyopathy 9.6
726 corpus luteum cyst 9.6
727 hepatic encephalopathy 9.6
728 coccidioidomycosis 9.6
729 hyperparathyroidism 9.6
730 beriberi 9.6
731 pharyngoconjunctival fever 9.6
732 familial hypercholesterolemia 9.6
733 hypophosphatasia 9.6
734 adult-onset still's disease 9.6
735 sclerosing cholangitis 9.6
736 capillary leak syndrome 9.6
737 46,xy sex reversal 9.6
738 prostatitis 9.6
739 panniculitis 9.6
740 diffuse scleroderma 9.6
741 breast fibroadenoma 9.6
742 neuroendocrine tumor 9.6
743 retinal vein occlusion 9.6
744 vascular cancer 9.6
745 ocular melanoma 9.6
746 vascular disease 9.6
747 thyroid gland cancer 9.6
748 pericarditis 9.6
749 islet cell tumor 9.6
750 status epilepticus 9.6
751 malignant skin fibrous histiocytoma 9.6
752 hyperuricemia 9.6
753 cholecystitis 9.6
754 fallopian tube disease 9.6
755 rectum adenocarcinoma 9.6
756 enthesopathy 9.6
757 myeloproliferative neoplasm 9.6
758 keratopathy 9.6
759 wernicke encephalopathy 9.6
760 central retinal vein occlusion 9.6
761 protein s deficiency 9.6
762 splenic infarction 9.6
763 hemangioma 9.6
764 corneal dystrophy 9.6
765 larynx cancer 9.6
766 contact dermatitis 9.6
767 rectosigmoid cancer 9.6
768 cerebellar disease 9.6
769 acute pancreatitis 9.6
770 glomerulonephritis 9.6
771 severe acute respiratory syndrome 9.6
772 anuria 9.6
773 antiphospholipid syndrome 9.6
774 breast ductal carcinoma 9.6
775 lobular neoplasia 9.6
776 malignant glioma 9.6
777 interstitial lung disease 9.6
778 tracheal stenosis 9.6
779 angiomyolipoma 9.6
780 breast adenocarcinoma 9.6
781 systemic mastocytosis 9.6
782 turner syndrome 9.6
783 mastocytosis 9.6
784 neurofibrosarcoma 9.6
785 duodenal obstruction 9.6
786 toxic encephalopathy 9.6
787 skin disease 9.6
788 gastric adenocarcinoma 9.6
789 cervical squamous cell carcinoma 9.6
790 pseudohermaphroditism 9.6
791 pleural empyema 9.6
792 porokeratosis 9.6
793 arthropathy 9.6
794 thrombophlebitis 9.6
795 lung squamous cell carcinoma 9.6
796 mouth disease 9.6
797 epithelioid cell melanoma 9.6
798 pustulosis of palm and sole 9.6
799 dyslexia 9.6
800 seminoma 9.6
801 macular retinal edema 9.6
802 rhinitis 9.6
803 pleomorphic adenoma 9.6
804 secretory meningioma 9.6
805 lymphoplasmacyte-rich meningioma 9.6
806 embryoma 9.6
807 cavernous hemangioma 9.6
808 peritoneal serous adenocarcinoma 9.6
809 ureter adenocarcinoma 9.6
810 adenocarcinoma in situ 9.6
811 pancreatitis 9.6
812 thyroid gland disease 9.6
813 adjustment disorder 9.6
814 pleural cancer 9.6
815 aortitis 9.6
816 urinary tract obstruction 9.6
817 benign struma ovarii 9.6
818 myxoid leiomyosarcoma 9.6
819 sleep disorder 9.6
820 ovarian endodermal sinus tumor 9.6
821 acute pyelonephritis 9.6
822 spinal canal intradural extramedullary neoplasm 9.6
823 mixed liposarcoma 9.6
824 chronic salpingitis 9.6
825 breast lymphoma 9.6
826 benign intermediate mesothelioma 9.6
827 malignant peripheral nerve sheath tumor 9.6
828 ovarian carcinosarcoma 9.6
829 ovarian endometrial cancer 9.6
830 acquired immunodeficiency syndrome 9.6
831 cowden syndrome 9.6
832 connective tissue disease 9.6
833 radiation cystitis 9.6
834 thyroiditis 9.6
835 premenstrual tension 9.6
836 enterobiasis 9.6
837 peptic ulcer disease 9.6
838 endocervical carcinoma 9.6
839 childhood leukemia 9.6
840 placenta disease 9.6
841 end stage renal disease 9.6
842 periodontitis 9.6
843 paralytic ileus 9.6
844 bullous pemphigoid 9.6
845 herpes zoster 9.6
846 reticulosarcoma 9.6
847 collagen disease 9.6
848 oropharynx cancer 9.6
849 myeloid sarcoma 9.6
850 crohn's disease 9.6
851 fascioliasis 9.6
852 actinic keratosis 9.6
853 psoriasis 9.6
854 leishmaniasis 9.6
855 macroglobulinemia 9.6
856 granuloma inguinale 9.6
857 achalasia 9.6
858 viral infectious disease 9.6
859 acute myocardial infarction 9.6
860 cholangitis 9.6
861 aphthous stomatitis 9.6
862 irritable bowel syndrome 9.6
863 drug dependence 9.6
864 myotonic dystrophy 9.6
865 ankrd26-related thrombocytopenia 9.6
866 bap1 tumor predisposition syndrome 9.6
867 dicer1 tumor predisposition 9.6
868 mutyh polyposis 9.6
869 acute erythroid leukemia 9.6
870 acute monoblastic leukemia 9.6
871 acute myeloblastic leukemia without maturation 9.6
872 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.6
873 biliary tract cancer 9.6
874 bowen's disease 9.6
875 broken heart syndrome 9.6
876 chromosome 9 inversion 9.6
877 congenital extrahepatic portosystemic shunt 9.6
878 desmoplastic small round cell tumor 9.6
879 diffuse gastric cancer 9.6
880 double inferior vena cava 9.6
881 embryonal sarcoma 9.6
882 familial colorectal cancer 9.6
883 fibromatosis 9.6
884 gliomatosis peritonei 9.6
885 heparin-induced thrombocytopenia 9.6
886 littoral cell angioma of the spleen 9.6
887 may-thurner syndrome 9.6
888 oncogenic osteomalacia 9.6
889 periodontal ehlers-danlos syndrome 9.6
890 precocious puberty 9.6
891 pure autonomic failure 9.6
892 refsum disease with increased pipecolic acidemia 9.6
893 remitting seronegative symmetrical synovitis with pitting edema 9.6
894 retroperitoneal liposarcoma 9.6
895 ring chromosome 2 9.6
896 ring chromosome 3 9.6
897 simpson-golabi-behmel syndrome 9.6
898 splenomegaly 9.6
899 subacute cerebellar degeneration 9.6
900 teratoma with malignant transformation 9.6
901 triploidy 9.6
902 uterine sarcoma 9.6
903 cerebral beriberi 9.6
904 paresthesia 9.6
905 tremor 9.6
906 paraneoplastic limbic encephalitis 9.6
907 posttransplant acute limbic encephalitis 9.6
908 isolated split hand-split foot malformation 9.6
909 autosomal dominant epidermolytic ichthyosis 9.6
910 drug-induced vasculitis 9.6
911 borderline epithelial tumor of ovary 9.6
912 atypical meigs syndrome 9.6
913 ovarian fibroma 9.6
914 mucinous adenocarcinoma of the appendix 9.6
915 avascular necrosis 9.6
916 zinc-responsive necrolytic acral erythema 9.6
917 secondary sclerosing cholangitis 9.6
918 non-severe combined immunodeficiency 9.6
919 acute liver failure 9.6
920 rare gynecological tumor 9.6
921 cardiogenic shock 9.6
922 monosomy 22 9.6
923 coronary ostial stenosis or atresia 9.6
924 rare coagulation disorder 9.6
925 precursor t-cell acute lymphoblastic leukemia 9.6

Graphical network of the top 20 diseases related to Ovarian Cancer 1:



Diseases related to Ovarian Cancer 1

Symptoms & Phenotypes for Ovarian Cancer 1

Clinical features from OMIM:

607893

UMLS symptoms related to Ovarian Cancer 1:


pelvic pain

Drugs & Therapeutics for Ovarian Cancer 1

Drugs for Ovarian Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 541, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
3
Fosaprepitant Approved Phase 4 172673-20-0 219090
4
Ifosfamide Approved Phase 4 3778-73-2 3690
5
tannic acid Approved Phase 4 1401-55-4
6
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
7
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
8
Ferrous fumarate Approved Phase 4 141-01-5
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Remifentanil Approved Phase 4 132875-61-7 60815
11
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
12
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
13
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
14
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
15
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
16
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
17
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
19
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
20 Neurotransmitter Agents Phase 4
21 neurokinin A Phase 4
22
Substance P Phase 4 33507-63-0 44359816
23 Progestins Phase 4
24 Follicle Stimulating Hormone Phase 4
25
Apatinib Phase 4 811803-05-1
26
Isophosphamide mustard Phase 4 0
27 Anesthetics Phase 4
28 Hypnotics and Sedatives Phase 4
29 Anesthetics, General Phase 4
30 Anesthetics, Intravenous Phase 4
31 Anesthetics, Inhalation Phase 4
32 Platelet Aggregation Inhibitors Phase 4
33 Antipyretics Phase 4
34
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
35
Hydralazine Approved Phase 3 86-54-4 3637
36
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
37
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
38
Epirubicin Approved Phase 3 56420-45-2 41867
39
Ethanol Approved Phase 3 64-17-5 702
40
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
41
Tranexamic Acid Approved Phase 3 1197-18-8 5526
42
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
43
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
44
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
45
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
46
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
47
Adenosine Approved, Investigational Phase 3 58-61-7 60961
48
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
49
Tamoxifen Approved Phase 3 10540-29-1 2733526
50
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
51
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
52
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
53
Atorvastatin Approved Phase 3 134523-00-5 60823
54
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
55
Selenious acid Approved, Investigational Phase 3 7783-00-8
56
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
57
Mebendazole Approved, Vet_approved Phase 3 31431-39-7 4030
58
Ibuprofen Approved Phase 3 15687-27-1 3672
59
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
60
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
61
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
62
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
63
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907